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ABSTRACT
Mov mouse strains differ from their respective, coisogenic partner strains by the embryonic, germ-line introduction of Moloney murine leukemia virus genomes. The possibility that retroviral insertions into the mouse genome resulted in gain or loss mutations at non-H-2 histocompatibility loci was investigated by reciprocal skin grafting between Mov mice and mice from coisogenic, background strains. Two B6-derived and eight 129-derived Mov strains were analyzed. B6 mice rejected skin from the viremic Mov-3 and Mov-14 strains, indicating that these mice had new histocompatibility antigens. No rejections were observed with reciprocal skin grafts exchanged between mice of the 129 background strain and 129-derived Mov strains, one of which (Mov-9) is viremic. To investigate the potential viral origin of the new histocompatibility antigen in Mov-14, lymphocytes from B6 mice primed in vivo with Mov-14 cells or skin were restimulated in vitro with Mov-14 spleen cells and with two retroviral-induced B6 lymphomas, MBL-2 and RBL-5. All three cell types stimulated cytotoxic lymphocytes that lysed Mov-14 Con A lymphoblasts, MBL-2 and RBL-5. The same cytotoxic lymphocytes lysed only lymphoblasts from the viremic Mov-9 strain when tested on cells from 129 and 129 Mov mice. Thus the insertion and expression of exogenous Moloney murine leukemia virus results in the appearance of a new histocompatibility antigen as defined by its stimulation of skin-graft rejection and cytotoxic effector T-cell generation. The non-H-2 histocompatibility antigen identified in this study has been designated H-43 and is encoded by genes mapping to different loci in different Mov strains. These observations suggest that at least a subgroup of non-H-2 histocompatibility antigens is encoded by endogenous retroviruses; the implications of these results for understanding the origin and the identity of non-H-2 histocompatibility antigens are discussed.
Multiple copies of endogenous retrovirus-related sequences map to numerous autosomal and sex-linked loci throughout the mouse genome. Interestingly, a considerable number of these endogenous retroviral sequences are associated with genes encoding non-H-2 histocompatibility antigens and lymphocyte differentiation antigens (1, 2) . The extent of this pattern of linkage suggests that it is not random, and the endogenous retroviral sequences may encode or regulate the expression of non-H-2 histocompatibility antigens. According to the latter possibility, retroviruses may act as insertional mutagens by interrupting normal gene expression or by activating expression of flanking genes. In fact, insertional mutations by retroviral integration have been observed in animals (3-7) as well as in tissue culture cells (8, 9) .
Studying the relationship between xenotropic virus-related sequences and non-H-2 histocompatibility mutations in mice, two "gain" mutants were observed to have lost restriction fragments homologous to the pXenv probe (10) . Examination of these data and those of others (2) revealed that in the majority of cases where endogenous retroviral sequences associated with histocompatibility alleles, the respective histocompatibility alleles specified either no detectable antigens or antigens more weakly detectable by skin grafting than the antigens specified by the alternate alleles. This inverse correlation suggested that non-H-2 histocompatibility mutations may be caused by insertion of retroviral sequences followed by histocompatibility gene inactivation. To test whether retroviral integration can affect expression of non-H-2 histocompatibility antigens, we analyzed a panel of inbred strains that were generated by either infection of mouse embryos with Moloney murine leukemia virus (MoMuLV) or injection of embryos with cloned provirus (11-13), followed by stable viral integration, for gain or loss of individual non-H-2 histocompatibility antigens. Contrary to initial expectations, we identified the gain of a cross-reactive histocompatibility antigen in Mov-14 and Mov-3 mice that stimulated the rejection of Mov-14 and Mov-3 skin grafts by coisogenic B6 hosts. This acquired antigen was also recognized by B6 anti-Mov-14 cytotoxic T lymphocytes in vitro and cross-reacted with an antigen(s) expressed by the Mov-9 strain on the 129 background and two B6 tumor lines.
MATERIALS AND METHODS
Mice. The viremic Mov-3 strain was initiated by infection of ICR strain mouse embryos with Mo-MuLV; subsequently, the stably integrated retroviral sequence was transferred to the C57BL/6 (B6) strain by 10 generations of backcrossing (13) . The viremic Mov-14 strain was derived by the microinjection of B6 male pronuclei with the cloned Mov-3 provirus with accompanying flanking sequence (14) . The Mov-5, Mov-6, Mov-7, Mov-8, Mov-9, Mov-10, Mov-11, and Mov-12 strains were derived by infection of 129 (SI ) mouse embryos with Mo-MuLV (12) . The Mov-9 strain is the only viremic strain on the 129 strain background. Therefore, with the exception of Mov-3, the employed Mov strains are truly coisogenic with their background strains. In all cases, experimental B6 and 129 strain mice were of the same substrain as that employed for the original Mov strain derivations.
Skin Grafting. Orthotropic tail skin grafting was performed as originally described (15) . Each recipient received two allografts and one autograft that were scored twice a week for the first 10 weeks and once a week thereafter. Grafts were scored for healthy epidermal scale pattern, pigment, and hair and were scored "rejected" when no viable signs were observed.
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Mixed Lymphocyte Culture (MLC). MLCs were performed by a modification (18) of the original procedure (19) . Cultures were performed in Click's medium (20) supplemented with 5% (vol/vol) fetal calf serum. Responder lymphocytes were spleen cells donated by recipients primed with either three sets of incompatible skin grafts or a single intraperitoneal injection of 10 x 106 incompatible spleen cells. Stimulator cells were H-2-compatible, non-H-2-incompatible spleen cells inactivated with 2000 R y irradiation (1 R = 2.58 x 10' C/kg), and H-2 compatible tumor cells inactivated with 6000 R y irradiation. Responders and stimulators were suspended to 5 x 106 cells per ml in Click's medium/fetal calf serum, mixed in equal proportions and incubated in a humidified atmosphere of 5% C02/95% air.
Cell-Mediated Lympholysis. The cell-mediated lympholysis assay was performed according to the technique described (19) . Target cells were Con A-induced lymphoblasts and tumor cells labeled with 51Cr; targets were delivered to quadruplicate round bottom wells of 96-well plates. Various numbers of cytotoxic effector cells, harvested at 6 days from non-H-2-incompatible MLCs, were added to yield effector/ target (E/T) cellular ratios as indicated, and the plates were incubated 4 hr at 37°C as above. The antigen-specific 51Cr release from labeled targets was determined as described (21) . Total releasable label was the 51Cr released during incubation with 2.5% (vol/vol) Triton X-100. Mean specific release (±SE) was determined for each E/T ratio; standard errors were always less than 10% ofthe mean percent release. blasts, MBL-2, and RBL-5 targets (Fig. 1) . All three stimulators stimulated CTL, which lysed Mov-14, MBL-2, and RBL-5 targets. Therefore, Mov-14 cells express an antigen that is cross-reactive with B6 lymphoma cells. The inability of 129 mice to reject skin grafts from the viremic Mov-9 strain was investigated with anti-Mov-14 CTL. B6 spleen cells were primed by Mov-14 spleen cell injection, boosted with Mov-14, MBL-2, or RBL-5, and maintained in culture by weekly restimulation with Mov-14 stimulators in the presence of rat Con A supernatant. CTL were tested in the cell-mediated lympholysis assay with targets from (i) B6, Mov-14, MBL-2, RBL-5, 129, and Mov-9 ( Fig. 2) and (ii) 129, Mov-5, -6, -7, -8, -9, -10, -11, and -12 ( 
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The family of non-H-2 histocompatibility genes was discovered by virtue oftheir expression as cell-surface determinants that were detectable by tissue transplantation (22, 23) and cytotoxic effector T cells (18, 24) . Although 42 autosomal non-H-2 histocompatibility loci have been identified by genetic analysis (23, 25) , non-H-2 histocompatibility gene products have eluded characterization due to their inability to stimulate antibody production. In fact, it is not at all certain that different non-H-2 histocompatibility gene products encoded by genes at the same locus are alloantigenic. Studies that have demonstrated tight linkage between a number of non-H-2 histocompatibility loci and xenotropic, mink cell focus-forming and ecotropic viral sequences (1, 2) have provided potential clues to the identity of non-H-2 histocompatibility loci. Further evidence for association of histocompatibility genes and retroviral sequences came from the observation that non-H-2 histocompatibility antigenicity in congenic and mutant strains inversely correlates with the presence of retroviral sequences (10) . Retroviral, insertional mutagenesis has been demonstrated to spontaneously occur in mice and tissue culture cells (3) (4) (5) (6) (7) (8) (9) . Given the tight linkage between retroviruses and non-H-2 histocompatibility genes, it is conceivable that mutations (gain or loss) at non-H-2 histocompatibility genes may occur by insertion of retroviral sequences. To directly test the hypothesis that non-H-2 histocompatibility antigens can be affected by retrovirus insertion, we analyzed a panel of inbred mouse strains that were generated by infection of mouse embryos with MoMuLV (12) (13) (14) for gain or loss of individual non-H-2 histocompatibility antigens.
No histocompatibility gene loss mutations were recorded but a new histocompatibility antigen was demonstrated in the viremic Mov-14 and Mov-3 strains on the B6 background. This histocompatibility antigen is defined by its ability to stimulate skin graft rejection and generation of CTL by B6 hosts. Because Mov-14 was generated by B6 pronucleus microinjection with cloned Mov-3 provirus plus 8 kilobases of ICR flanking sequences, the cross-reaction between Mov-14 and Mov-3 could have been due to the same histocompatibility antigen encoded by ICR strain flanking sequences (26) . Accordingly, the typing of different inbred strains for alleles at single non-H-2 histocompatibility loci may be partially incorrect; the original typing by complementation testing was based on the assumption that genes encoding histocompatibility antigens defined by a specific congenic strain combination were alleles mapping to a single histocompatibility locus (27) . The differential mapping of genes encoding H-43 in different Mov strains suggests that this may not always be a correct assumption. The presence of H-43 on Mov-9 cells was not detected by skin grafting, although Mov-9 Con A blasts were lysed by B6 anti-Mov-14 CTL (anti-H-43). There appear to be two possible explanations for this observation: (i) H-43 is expressed on Mov-9 lymphoid cells but not on Mov-9 skin cells, and (ii) 129 mice are genetically unresponsive to H-43. Consistent with the first explanation is the observation that the point of integration of Mo-MuLV can affect tissue-specific demethylation of proviral enhancer sequences (28) , which in turn may affect the tissue-specific expression of this provirus. The latter explanation may be based on a slight difference in H-2b-associated molecules in B6 (H-2b) and 129 (H-2bc) mice or to defective 129 non-H-2 immunoresponse genes; non-H-2 genetic control of Moloney lymphoma outgrowth has been described in other systems (29) .
The established association between retroviral sequences and non-H-2 histocompatibility genes, as well as the observations reported in this communication, have direct implications for our understanding of the origin and identity of non-H-2 histocompatibility genes. The only non-H-2 histocompatibility gene whose genetic origin has been identified is H-3; experimental data suggest that one of the H-3 gene products is 82 microglobulin (30, 31) . However, definitive proof in this system awaits the demonstration that transfection of cells with the cloned 12 microglobulin gene results in the expression of H-3 antigens. A comparable circumstance was indeed generated in vivo by the establishment of Mov mouse strains that are truly coisogenic with their respective background strains. The observations reported herein indicate that H-43 expression correlates with expression of Mo-MuLV sequences introduced into Mov mice at the embryo stage. Therefore, this is the first definitive identification of the origin of a non-H-2 histocompatibility antigen in which the expression of a new histocompatibility antigen can be directly attributed to the germ-line insertion of a new, identified gene. The retroviral origin of non-H-2 histocompatibility antigens has been evoked to explain (32) the variable frequency of mutations at non-H-2 histocompatibility loci in mice maintained in different environmental conditions; more stringent health control correlated with reduced histocompatibility mutation rates. This observation prompted the proposal that histocompatibility mutations were the result of integrations of viral genomes into germinal cells of parents of non-H-2 mutants. In light of several observations, this early proposal may have been truly prophetic for a specific class of non-H-2 histocompatibility genes but it is expected that the family of non-H-2 histocompatibility antigens is diverse, with many different origins and functions. It has long been proposed that non-H-2 histocompatibility antigens serve as a model antigen system for tumor-specific transplantation antigens. The similarity of the two systems derives from the observations that both classes of antigens elicit (i) slow rejection of grafts, (ii) major histocompatibility antigen class I-restricted and regulated CTL responses only after in vivo priming, and (iii) no antibody or limited antibody production. The demonstration that H-43 expression requires expression of Mo-MuLV sequences not only confirms the validity of non-H-2 histocompatibility antigens as a tumorspecific transplantation antigen model system but indicates that in certain situations, they are actually tumor-specific transplantation antigens.
